Nuvilex Completes Acquisition of Exclusive Worldwide Rights to Live-Cell Encapsulation Technology for Diabetes

Published: Nov 07, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SILVER SPRING, Md., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has acquired the exclusive worldwide rights to use the cellulose-based live-cell encapsulation technology for the development of treatments for diabetes from SG Austria Pte. Ltd.

Help employers find you! Check out all the jobs and post your resume.

Back to news